No significant association was found between inflammatory marker levels and the selected toxicity endpoints (p>0.05 in all cases). Figure 2 shows the distribution of cytokine levels at both time points stratified by pts who showed (label "tox") or did not show (label "no-tox") the selected toxicity endpoints.
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Conclusion
In this cohort the addition of CT to RT is associated with improved LC for T2 HPSCC. Patients with larger tumours were more likely to experience local failure after RT, and for this group treatment intensification with CTRT may be of benefit, even in node negative patients.Competing risk analysis has been used to account for the risk of early distant failure or death and censure in node positive patients receiving CTRT. Moreover, local failure is known to remain the predominant site of first recurrence, and risk of local failure is known to be increased, in node positive patients after CTRT. Tumour biology or first site of failure variation between the two groups is therefore unlikely to explain the significant difference in LC identified. 
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Purpose or Objective
Hair loss is a common complication of brain tumor radiotherapy but has not been reported following conventional radiotherapy of nasopharyngeal carcinomas (NPC). The use of posterior fields during intensity modulated radiotherapy (IMRT) of NPCs made hair loss common. The aim of this study was to evaluate all patients treated with IMRT for NPC to determine correlation between scalp doses and hair regrowth.
Material and Methods
Twenty-one patients treated with IMRT for NPC were prospectively followed during the radiotherapy period and up to 6 months after the end of the irradiation. All patients had 7 fields irradiation including a posterior field. A simultaneous boost technique was used to deliver 69.96 Gy in 33 Fractions to the nasopharynx and involved lymph nodes. The scalp was not considered as an organ at risk during radiotherapy planning. To evaluate the doses received, we have delineated the tissue between the skin and the skull taking as an upper limit 6 mm above the upper edges of the posterior field. We then reported the maximum dose (Dmax), the minimum dose (Dmin), the mean dose (Dmean), the percentage of volume receiving more than 10 Gy (V10Gy), the percentage of volume receiving more than 20 Gy (V20Gy) and the dose received by 50% of the scalp (D50%). After the end of treatment, patients were followed in consultation at 1 month, 3 months and 6 months to determine the hear regrowth. Mann-Whitney test was used to compare doses between patients with total and partial regrowth at 3 months.
Results
The median Dmax, Dmin and Dmean were 42.77 (31.86-63.98), 1.32 (0.9-1.96) and 16.11 (12.42-20.66) respectively. The median D50%, V10Gy and V20Gy were 16.91 
Conclusion
During IMRT for NPC a Mean dose of 16 Gy is responsible for acute hair loss in 100% of cases. However, this loss is only transient with partiel regrowth from 1 month of the end of treatment and a total regroth at 6 months in almost all cases. The considereation of scalp as an organ at risk during treatment planning would be necessary. Since the dose limits to be respected are not reported in the literature for the irradiation of the NPC, we propose, through the results of ou study, a Dmean < 16 Gy, V10Gy < 68% and V20Gy < 35%.
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